definiens: as defined in the Multi - Target Agreement ) to an actual or potential Third Party Manufacturing, Developmen t or Commercialization collaborator, Distributor, contra ctor or partner with respect to any Licensed Produc t or any CD38 SLT - A Fusion Protein contained therein or any Component thereof or otherwise as may be necessary or useful in connection with its exercise of rights or performance of obligations hereunder ( including in connection with any litigation with respect thereto ) or under the Multi - Target Agreement ; provided, that such Thi rd Party recipient is, if practicable, then subject to oblig ations of confidentiality and limitations on use of such Confidential Information substantially similar to those containe d herein ; ( f ) by Takeda or to an actual or potential investor in or acquirer of the business to which this Agreement or the Multi - Targe t Agreement relates ; provided, that ( i ) such Third Party recipient is then subject to obligations of confide ntiality and limitations on use of such Confidentia l Information substantially similar to those contained herein and ( ii ) Takeda shall provide at least [ * * * ] prior not ice of ( including a copy of ) any such proposed disclosure to MTEM and shall not make any such disclosure without first o btaining MTEM ’s prior written consent ( which consent shall n ot be unreasonably withheld, conditioned or delayed ) with respect thereto in each instance ( it being understo od that if consent with respect to a specific discl osure is given by MTEM with respect to a particular type of audien ce of Third Parties ( e.g., investors not affiliated with a pharmaceutical company ), Takeda may subsequently ma ke such specific disclosure to another member of su ch audience consistent with such consent without obtai ning specific consent from MTEM in such instance ) ; and ( g ) by MTEM to actual or potential strategic partners, investors or acquirers ; provided, that such disclosures shall be limited to the terms of this Agreement and pre - clinical data and pre - clinical results arising out of the Early Stage Program and shall be limited disclosures that do not divulge or otherwise make available the identity of any CD38 SLT - A Fusio n Protein or the targeting moiety contained therein ; provided, further, that ( i ) such Third Party recipient is the n subject to obligations of confidentiality and lim itations on use of such Confidential Information substantially similar to those contained herein, and ( ii ) MTEM shall pro vide at least [ * * * ] prior notice of ( including a copy of ) any suc h proposed disclosure to Takeda and shall not make any such disclosure without first obtaining Takeda ’s prior w ritten consent ( which consent shall not be unreason ably withheld, conditioned or delayed ) with respect ther eto in each instance ( it being understood that if c onsent with respect to a specific disclosure is given by Takeda with respect to a particular type of audience of T hird Parties ( e.g., investors not affiliated with a pharmaceutical co mpany ), MTEM may subsequently make such specific disclosure to another member of such audience consi stent with such consent without obtaining specific consent from Takeda in such instance )